July 25, 2012

Sanofi Pasteur’s Dengue Vaccine Demonstrates Proof of Efficacy

- Early data analysis confirms excellent safety profile and shows vaccine ability to protect against disease caused by three of the four dengue virus serotypes circulating in Thailand in world’s first ever efficacy study -

 

Sanofi Pasteur’s Dengue Vaccine Demonstrates Proof of Efficacy
- Early data analysis confirms excellent safety profile and shows vaccine ability to protect against disease caused by three of the four dengue virus serotypes circulating in Thailand in world’s first ever efficacy study -

Lyon, France – July 25, 2012 – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its tetravalent dengue vaccine candidate demonstrated proof of efficacy against dengue, a threat to almost 3 billion people, in the world’s first ever dengue efficacy trial conducted in Thailand, with excellent safety.